Keith Blundy

Keith joins PharmEnable as the Investor Director from Cambridge Enterprise. He has experience in drug discovery, strategy, and licensing as well as extensive venture capital fundraising experience gained as CEO of both Cancer Research Technology (CRT – CRUK’s world-leading cancer technology commercialization company) and a pioneering biotech start-up (Storm Therapeutics Ltd). He was formerly a director of KuDOS Pharmaceuticals Ltd, Mission Therapeutics, Cancer Therapeutics Pty and Inivata Ltd. Keith has a BSc and Ph.D. in genetics and an MBA from the London Business School.